Clopidogrel-induced systemic inflammatory response syndrome.

Mayo Clin Proc

Department of Medicine E, Institute of Oncology, The Sheba Medical Center, Tel-Hashomer, Israel.

Published: May 2003

Clopidogrel bisulfate, a widely used inhibitor of platelet aggregation, is considered at least as safe as aspirin. We describe a patient who developed a systemic inflammatory response syndrome consisting of high fever, tachycardia, cellulitis-like rash, impaired liver function, and mild leukopenia after receiving clopidogrel before coronary angiography and stent implantation. The reaction resolved promptly after withdrawal of the drug and recurred shortly after a rechallenge dose was administered, thus making the diagnosis of a clopidogrel-induced reaction highly probable. Recognition of this clopidogrel-induced syndrome is extremely important, both for rapid discontinuation of the offending drug and for avoidance of unnecessary drug therapy or invasive procedures.

Download full-text PDF

Source
http://dx.doi.org/10.4065/78.5.618DOI Listing

Publication Analysis

Top Keywords

systemic inflammatory
8
inflammatory response
8
response syndrome
8
clopidogrel-induced systemic
4
syndrome clopidogrel
4
clopidogrel bisulfate
4
bisulfate inhibitor
4
inhibitor platelet
4
platelet aggregation
4
aggregation considered
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!